Solvay Biologicals Completes Validation For Its Cell-Based Production Facility

Solvay Biologicals has completed the validation for its cell-based production facility following a successful inspection by the Dutch authorities. The company said that the 3,900m2 facility in Weesp uses the latest technology in cell culturing for the production of influenza vaccines.

Reportedly, the validation of the new cell-based production facility will enable Solvay Pharmaceuticals to respond even better to the growing worldwide demand for influenza vaccines as it expands company’s production capacity beyond its current egg-based manufacturing plant.

In parallel, Solvay Pharmaceuticals has also announces the registration of the first trivalent adjuvant cell-based seasonal influenza vaccine Grippol Neo in Russia.

Grippol Neo is a seasonal influenza vaccine based on influenza antigens produced by Solvay Biologicals in its cell-based facility and Petrovax’s proprietary adjuvant Polyoxidonium.

The company said that the new preservation free vaccine is formulated in a fully ISO and GMP certified facility of Petrovax near Moscow. Grippol Neo will be marketed in Russia during the upcoming influenza season of 2009/2010.

Sjirk Kok, executive vice president of Solvay Biologicals, said: “The validation of our new, state-of-the-art cell-based production plant will enable Solvay Pharmaceuticals to contribute even more to the protection of millions patients around the world against the influenza virus.”